ERO1A and neoplasm: Consistent with the in vitro results, SLC7A11 re-expression abrogated the suppressive effects of ERO1α depletion on xenograft growth, tumor cell proliferation (as assessed by the Ki-67 index), and tumor angiogenesis (as assessed by the CD31 index) (Fig. 5K–O).